Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
Pancreatic adenocarcinoma is a devastating disease with only 15–20% of patients resectable at diagnosis. Neoadjuvant chemotherapy for this cohort is becoming increasingly popular; however, there are no published randomized trials that support the use of neoadjuvant chemotherapy over upfront surgery...
Main Authors: | Sarah Maloney, Malinda Itchins, Jennifer Arena, Sumit Sahni, Viive M. Howell, Sarah A. Hayes, Anthony J. Gill, Stephen J. Clarke, Jaswinder Samra, Anubhav Mittal, Nick Pavlakis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/12/2700 |
Similar Items
-
Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
by: Sumit Sahni, et al.
Published: (2020-03-01) -
Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
by: Ren X, et al.
Published: (2019-01-01) -
Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
by: Quisette P. Janssen, et al.
Published: (2020-01-01) -
Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?
by: Fuyuhiko Motoi, et al.
Published: (2020-03-01) -
Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
by: Kosuke Ono, et al.
Published: (2021-04-01)